Will FMC's new active ingredient revenue reach $300M in FY2026?

The $300M target requires 50% YoY growth ($200M to $300M). FMC achieved 54% growth in 2025 ($130M to $200M), but missed the $250M target by 20%. The molecules are genuinely differentiated — Godelix is the first new MOA herbicide in 30+ years. Registration progress is the key variable: fluindapyr is registered in all major markets, but Isoflex had UK delays and Brazil direct sales underperformed in 2025. The $300M floor of the $300-400M range requires solid execution but is not the most optimistic scenario. Management has additional molecules in development. The 2025 miss was driven by specific registration delays, not fundamental demand issues. If registrations proceed on schedule, $300M is achievable. ~48% reflects the tension between genuine demand and execution risk.

The growth trajectory supports the $300M target: $130M (2024) to $200M (2025) represents 54% growth. Extrapolating at a more conservative 40% would yield $280M — close but below $300M. To reach $300M, FMC needs the registrations to come through on time and Brazil direct sales to perform. The 2025 shortfall was specifically attributed to UK Isoflex delays and Brazil execution — both fixable. Fluindapyr is now registered globally and Godelix has emergency registrations. The pipeline's long-term trajectory ($2B+ by 2035) suggests significant market pull. I give slightly above 50% probability that $300M is reached, reflecting the genuine molecule quality offset by execution track record uncertainty.

The resolution criteria include 'or if FMC does not disclose this metric separately' — resolving NO. If FMC changes its reporting or merges new AI into broader categories, this resolves NO. Beyond that disclosure risk, the fundamental question is whether the 2025 miss pattern ($200M vs $250M, or 80% achievement) repeats. If the same 80% achievement rate applies to 2026's $300-400M target, the result would be $240-320M — the bottom of which would resolve NO. Registration timing creates genuine quarterly volatility. The probability of reaching exactly $300M is near coin-flip given the 2025 execution miss.

Near coin-flip. The molecules are strong (genuinely differentiated, unmet market needs), but FMC missed the 2025 target. The growth rate needed (50% YoY) was achieved last year but from a smaller base. As the base grows, maintaining percentage growth rates becomes harder. However, more molecules are registering in more markets, which expands the addressable revenue pool. The $300M floor is achievable if Isoflex UK registration comes through and Brazil execution improves. ~50% reflects genuine uncertainty about execution timing vs molecule quality.

The 2025 miss was 20% below target. If a similar execution gap applies to 2026, the result would be $240-280M — well below $300M. FMC's operational challenges (restructuring, balance sheet stress) may distract from commercial execution of new molecules. Sales teams focused on defending legacy products may not optimize new AI sales efforts. However, the new molecules sell themselves to some extent — addressing unmet needs in resistance management. The question is whether FMC's go-to-market capacity is sufficient during a distressed period.

Key consideration: the $300M threshold is the bottom of management's $300-400M target range. Management targets tend to reflect best-case scenarios, especially from a company with a track record of overoptimism. However, the 54% growth rate from 2024 to 2025 demonstrates strong underlying demand. If growth decelerates to a still-healthy 40%, the result is $280M — just below threshold. At 50% growth, $300M. The probability of exceeding 50% growth is ~48%, reflecting the strong molecular pipeline offset by execution risk and the harder comparison base.

2025 grew 54% but missed target by 20%. Achieving $300M requires 50% growth. Molecules are strong but execution has been inconsistent. Registration timing creates uncertainty. Near coin-flip slightly below 50%.

Genuinely uncertain. The molecules are differentiated and in demand. But FMC's operational distress could impair commercial execution. More registrations expand the market. 2025 miss was from specific delays. If delays don't repeat, $300M is achievable. True coin-flip.

The $300M target is achievable but not the base case given 2025 execution track record. Growth trajectory supports it but management tends to set optimistic targets. Slightly below 50% to reflect execution risk discount on otherwise strong demand.